Background
==========

Preclinical animal models of human tumors represent a major tool for the selection and development of effective anticancer agents. There is a considerable number of well characterized human cancer cell lines, many of which can be grown as solid tumors (either subcutaneously or orthotopicaly) in immunodeficient mice. The ease of use and low cost of these models make them desirable for screening *in vivo*activity of anticancer compounds as compared to induced or transgenic rodent tumor models. Rodent models also allow pharmacodynamic and pharmacokinetic parameters to be directly measured and related to antitumor efficacy. Commonly used human cancer cell lines, such as the panel of 60 lines (NCI60) used by the Developmental Therapeutics Program at the National Cancer Institute, have been extensively studied at the molecular level *in vitro*and to a lesser extent *in vivo*. Recent advances in genomic technology allow molecular characterization of these models to an extent never before possible using RNA expression profiling, comparative genomic hybridization, proteomic and metabonomic profiling. Ross *et al*. \[[@B1]\] looked at the *in vitro*gene expression in the NCI60 panel. The gene expression pattern for many lines indicated a relationship with the tumor tissue of origin and also correlated with doubling time and drug metabolism. Virtanen *et al*. \[[@B2]\] have analyzed the expression patterns of 85 lung tumor samples from both clinical samples and established tumor lines. The fresh tumors clustered according to pathological subtype with many of the cell lines also clustering within the same groups. Pedersen *et al*. \[[@B3]\] performed a similar study with human small cell lung cancer cell lines and compared them to ressected tissue samples. Dan *et al*. \[[@B4]\] recently performed RNA expression profiling on 39 human cancer cell lines and related the gene expression patterns to chemosensitivity of 55 anticancer agents. Zembutsu *et al*. \[[@B5]\] performed a similar study but profiled 85 human cancer xenografts.

What was apparent in all these studies was that each tumor model was distinctly different and could be distinguished from related models using routine data analysis methods. Furthermore, it appears that it is possible to identify models that are no longer true to their origins. Ross *et al*. \[[@B1]\] identified MDA-MB-435 as a possible melanoma derived line, which is at odds with its supposed origins of a metastatic breast carcinoma \[[@B6]\]. However, such identification also raises the possibility that the sample that Ross *et al*. obtained was not the true \"MDA-MB-435.\" Clearly there is the opportunity to use profiling technology as an advanced quality control method that could not only identify mislabeled tumor lines but possibly genetic drift.

While these reports have tremendous value they do not address some basic questions about human tumor models that could impact the design of *in vivo*drug development studies. For example, most, if not all, xenografts demonstrate Gompertzian growth kinetics with continuously increasing doubling times as they grow larger \[[@B7]\]. Despite this obvious change in biology, it is unknown whether xenografts alter their expression as they increase in size or whether expression differences exist for the same tumor line grown both as a solid tumor in a mouse or in tissue culture. To investigate these questions we grew human colon tumors (HCT-116 and Colo205) in Nu/Nu mice and harvested tumors at three sizes (200 mg, 500 mg, 1000 mg). Isolated RNA was analyzed on Affymetrix GeneChips. The effect of mouse strain on tumor gene expression was also investigated by comparing tumors at 500 mg grown in Nu/Nu and C.B-17 SCID mouse strains. Lastly we profiled additional tumor models to investigate the changes in gene expression that occur when a tumor line is grown *in vivo*or *in vitro*.

Methods
=======

Xenograft and tissue culture methods
------------------------------------

Cell lines were grown in DMEM/F12 supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, California). They were passaged in 75-cm^2^tissue culture flasks in an atmosphere of 5% CO~2~in air and were subcultured weekly, using 0.05% trypsin EDTA (Invitrogen, Carlsbad, California). RNA from tissue culture samples was harvested at mid-log phase. Human tumor xenografts were grown in either Nu/Nu mice or C.B-17 SCID female mice obtained from Charles River Laboratories (Wilmington, Massachusetts) between four and five weeks of age. Mice were housed five to a cage in animal rooms maintained at between 21--25°C with a 12 h alternating dark/light cycle. All animal studies were conducted under Veterinary Use Protocols approved by the Institutional Animal Care and Use Committee. Tumors were maintained by serial passage of 30 mg tumor fragments between animals, implanted subcutaneously into the right axillary region using a trocar needle aseptically. Tumors were passed when the primary had reached between 500 and 1000 mg and were never passed more than ten times. Tumor growth was followed by caliper measurements of perpendicular measures of the tumor. The weight in mg was estimated by the formula: tumor weight = a(b^2^)/2, where a and b are the tumor length and width respectively in mm. Tumor tissue was harvested immediately following animal sacrifice by excising the tumor and powdering it in a liquid nitrogen cooled crucible and pestle. Tumor powder was stored at -80°C until RNA isolation.

Affymetrix GeneChip
-------------------

RNA was extracted using TRIZOL^®^reagent (Invitrogen, Carlsbad, California) according to the manufacturer\'s protocol. RNA integrity was monitored using denaturing agarose gel electrophoresis in 1X MOPS. Biotinylated target RNA was prepared from 15 μg of total RNA using the Affymetrix protocol. Briefly, double-stranded cDNA was prepared from the RNA template using a modified oligo-dT primer containing a 5\' T7 RNA polymerase promoter sequence and the Superscript Choice System for cDNA Synthesis (Invitrogen, Carlsbad, California). Following phenol-chloroform extraction and ethanol precipitation, one-half of the cDNA reaction (0.5 -- 1.0 μg) was used as the template in an *in vitro*transcription reaction containing T7 RNA polymerase, a mixture of unlabeled ATP, CTP, GTP, and UTP, and biotin-11-CTP and biotin-16-UTP (BioArray High Yield Kit, ENZO, Farmingdale, New York). The resulting biotinylated-cRNA \"target\" was purified on an affinity resin (RNeasy, Qiagen, Valencia, California) and quantified using the convention that 1 O.D. 260 nm corresponds to 40 μg/mL of RNA. Typical yields ranged from 50 -- 100 μg with transcript sizes between 3.0 to 0.25 kilonucleotides as determined by denaturing gel electrophoresis. Fifteen micrograms of biotinylated cRNA was randomly fragmented to an average size of 50 nucleotides by incubating at 94°C for 35 minutes in 40 mM TRIS-acetate, pH 8.1, 100 mM potassium acetate, and 30 mM magnesium acetate. The fragmented cRNA was hybridized in a solution containing 100 mM MES, 1 M \[Na^+^\], 20 mM EDTA, 0.01% TWEEN 20, 50 pM of Control Oligonucleotide B2, 0.1 mg/mL of sonicated herring sperm DNA, and 0.5 mg/mL BSA for 16 hours at 45°C on either the Human U95A or the Mouse U74A Affymetrix GeneChips^®^(Affymetrix, Santa Clara, California). Each hybridization included a mixture of four bacterial biotinylated-RNA transcripts (BioB, BioC, BioD, and cre) spiked at 1.5, 5, 25, and 100 pM, respectively. The hybridization reactions were processed and scanned according to the standard Affymetrix protocols.

Data analysis
-------------

All arrays were global scaled to a target intensity value of 600 using the standard Affymetrix protocol. Calculation of the scaling factor, background, noise and percent present, was performed according to Affymetrix protocols using the Data Mining Tool (Affymetrix Santa Clara, California). All resulting data sets were filtered using the absolute call metric (present or absent) using Microsoft Access (Microsoft Corporation, Redmond, Washington). Genes selected had expression levels classified as present at least once in the samples selected for the particular analysis.

To determine the relationship between tumor samples harvested at different sizes the filtered RNA profiling data was analyzed with classic multidimensional scaling (MDS), implemented in R \[[@B8],[@B9]\]. MDS is an unsupervised learning technique that attempts to preserve the relationship between points from high dimensional space at lower dimensional spaces. The program R is a free integrated suite of software facilities for data manipulation, calculation and graphical display <http://www.r-project.org>.

Analysis of variance (ANOVA) was used to test the effects of tumor size and tumor line, using the following model: *Expression of gene*~i~*\~ tumor.size + tumor.line + tumor.line\*tumor.size*. To test the effect due to mouse background, we used the following model: *Expression of gene*~i~*\~ mouse background*. RNA profiling data filtered on the absolute call metric was used for this analysis and ANOVA was implemented in R. ANOVA is a statistical linear modeling procedure that partitions the total variance into parts corresponding to various sources in the model \[[@B10],[@B11]\]. It has been used previously in microarray data analysis \[[@B12]-[@B15]\].

To rigorously select genes with expression differences between samples, ANOVA p-values were adjusted using multiple comparison procedures. Multiple comparison procedures are tools to adjust p-values that might be inflated as a result of performing multiple hypothesis tests. The Benjamini and Hochberg procedure controls the false discovery rate, which is the expected fraction of false discoveries in all rejected hypothesis \[[@B16]\]. This procedure is less stringent than methods controlling the family wise error rate (e.g. the Bonferroni correction); hence it is more powerful.

Hierarchical clustering was performed in GeneSpring 5.0 (Silicon Genetics, Redwood City, California). The distinction calculation from Spotfire DecisionSite 6.2 (Spotfire Inc. Somerville, Massachusetts) was used to select genes differentially expressed in xenograft samples or tissue culture samples. All data from the tissue culture samples that had an *in vivo*pair (8 samples) were selected into one group and all data from the xenograft samples (8 samples) were selected into a second group. Genes were prefiltered using the absolute call metric by selecting genes that were present at least once in the selected samples. A distinction value score and p-value was calculated for each gene. The score (≥1) and p-value (≤0.001) was then used to select genes that were differentially expressed between xenograft samples and tissue culture samples. To functionally classify gene lists, web resources such as NCBI (National Center for Biotechnology Information, <http://www.ncbi.nlm.nih.gov/>) were searched and the data compiled. Further searching for gene associations in PubMed (NCBI) was also performed.

Results
=======

Variation in tumor xenograft gene expression due to size
--------------------------------------------------------

We focused on two human colon carcinoma xenografts (HCT-116 and Colo205) to investigate the effects of tumor size and mouse strain on gene expression. Samples were harvested in quadruplicate at three different tumor sizes (200 mg, 500 mg and 1000 mg) for both tumor models grown in Nu/Nu mice (except for the 500 mg sample of Colo205 where five samples were harvested). These sizes were selected as they represent the range at which sensitivity to anticancer agents are traditionally tested and because most models approximate log-linear growth at these sizes. RNA expression profiling data was obtained from Affymetrix U95A GeneChips containing approximately 12600 genes. Genes present (above background) once or more across all samples were selected for further analysis (approximately 7600 genes).

Initial analysis of the expression data with multi-dimensional scaling (MDS) showed that samples from the same tumor line clustered together and that there was clear separation between samples from HCT-116 and Colo205 (Figure [1](#F1){ref-type="fig"}). Compared to the profound effect due to tumor line, there was no clear separation among samples of different sizes in the MDS plot, suggesting that there was little alteration in gene expression due to differences in tumor size (tumor size effect).

The result from MDS was further confirmed by analysis of variance (ANOVA). Using ANOVA we modeled the effects of tumor line and tumor size on gene expression. Since in the ANOVA we conducted approximately 7000 statistical tests (on the selected genes), with a p-value cutoff of 0.01, we would expect approximately 70 genes (1% of 7000) scored as significantly changed due to chance alone. Indeed, the observed number of significantly changed genes (p ≤ 0.01) due to tumor size effect was 154, approximately twice what was predicted by chance alone (Figure [2](#F2){ref-type="fig"}). In contrast, the number of significantly changed genes due to tumor line effect (4731 genes p-value \< 0.01) was far greater than chance alone, indicating the two tumor lines were extremely different as suggested by MDS. The distribution of p-values confirmed the profound effect of tumor line on gene expression with genes affected at all expression levels (Figure [3](#F3){ref-type="fig"}).

To rigorously identify genes that may suggest functionally significant changes as a tumor increases in size from 200 mg to 1000 mg the ANOVA p-values were adjusted using multiple comparison procedures. Following this analysis none of the previously identified 154 genes had p-values \< 0.05. This indicated that there was no change in gene expression as a human tumor xenograft increased in size from 200 mg to 1000 mg. This was true for both the HCT-116 and the Colo205 tumor lines.

Variation in tumor xenograft gene expression due to mouse strain
----------------------------------------------------------------

Additional RNA samples were prepared from 500 mg HCT-116 tumors grown in C.B-17 SCID mice and hybridized to Affymetrix U95A GeneChips. The expression data were compared to data from the same line grown in Nu/Nu mice harvested at 500 mg. The MDS analysis showed there was no distinct separation or grouping for samples from the two different mouse strains (Figure [1](#F1){ref-type="fig"}). This suggests that mouse strain played only a small role in altering the expression profiles of HCT-116 tumor samples. However, ANOVA did reveal that considerably more genes were altered in their expression due to the mouse background (493 genes) compared to chance alone (p \< 0.01). To identify genes that may suggest biologically significant differences due to the mouse background effect, the ANOVA p-values were adjusted using multiple comparison procedures. Using the Benjamini and Hockberg procedure \[[@B16]\] 63 genes were found to have a p-value \< 0.05 with 32 genes increased in the C.B17-SCID strain and 31 increased in the Nu/Nu strain (Table [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Functional classification of these genes using a gene ontology approach did not identify functions that could be linked to known biological pathways. Therefore a biological understanding of the changes in gene expression due to mouse strain remains elusive.

Comparison of lines grown in both tissue culture and solid tumor xenografts
---------------------------------------------------------------------------

To explore the relatedness of different tumor lines to each other and to investigate the gene expression differences between growth in tissue culture and growth as a subcutaneous solid tumor, RNA samples were prepared from the 13 human tumor lines grown in tissue culture to mid-log phase (Table [3](#T3){ref-type="table"}). An additional eight RNA samples were obtained of the same lines grown as xenografts in Nu/Nu mice. The gene expression profiling data resulting from hybridizing the 21 samples to Affymetrix U95A GeneChips was filtered for genes classified as present at least once across all samples.

Hierarchical clustering analysis using Spearman rank for samples and Pearson correlation for genes was used to determine the relationship between 13 different human tumor lines (Figure [4](#F4){ref-type="fig"}). The clustering analysis revealed that for each individual tumor line the xenograft and tissue culture profiles were more similar to each other than any other profile (with one exception). That is, tumor lines clustered together based on their genotypes rather than their growth conditions, suggesting \"nature\" (genotype) was more influential than \"nurture\" (growth conditions). This result was confirmed with MDS and principle component analysis (data not shown). The one exception from this pattern was the xenograft sample of ZR-75-1, which did not cluster on the same node as the ZR-75-1 sample grown in tissue culture. However, subsequently we have found that our xenograft ZR-75-1 line has aberrant biological characteristics that are inconsistent with the known phenotypes of this line.

Although each tissue culture-xenograft sample did cluster together there were many gene changes between the paired samples (Table [4](#T4){ref-type="table"}). When fold change values were calculated for each tissue culture xenograft pair and the number of genes with ≥2 fold-change tabulated there was a median of 425.5 genes increased in xenografts and 387 decreased. Again the ZR-75-1 sample was aberrant with many more gene changes than the other lines.

Another striking feature revealed by clustering analysis was that none of the tumor lines were particularly similar to each other. The tumor lines did not necessarily cluster based upon the tissue of origin from which each line was thought to be derived. However, a group of breast carcinoma lines that did cluster together (BT474, ZR-75-1, MDA-MB-453, MCF-7, SKBr-3 and MDA-MB-468), although MDA-MB-435 and MDA-MB-231 did not cluster with this group. The two lung carcinoma lines (H2009 and H125) did cluster closely, but MDA-MB-231 and HCT-116 (colon carcinoma) also clustered with this group. MDA-MB-435 and Colo205 clustered independently from all groups.

Selection and functional assessment of differential expressed genes in xenograft or tissue culture samples
----------------------------------------------------------------------------------------------------------

Since genes that are co-expressed in a particular environment may provide information about the adaptive changes to the environment, we identified genes that showed a pattern of high expression in xenograft samples or tissue culture samples using Spotfire\'s DecisionSite calculation. This analysis identified a small number of genes that matched either pattern. There were 36 genes with increased expression in the xenograft samples relative to the tissue cultures samples and 17 genes that showed high expression in the tissue culture samples relative to the xenograft samples (Figure [5](#F5){ref-type="fig"}). Functional classification of these genes showed that they separated into distinct functional groups (see Table [5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}). Many of the genes consistently expressed in tissue culture samples encoded proteins involved in cell division, cell cycle, transcription and translation. In contrast, genes expressed in xenograft samples encoded proteins involved in extracellular matrix, cell adhesion, cell surface receptors transcription and translation.

Discussion
==========

The first part of our study was designed to address whether gene expression patterns in xenografts varied with tumor size. No significant changes (p-value \< 0.05) were found in any genes after statistical analysis of the RNA profiling data. This was a somewhat surprising result as there is evidence to suggest that tumors show size-dependent biological variation in both a clinical setting and as implanted solid tumors in rodents. It is generally assumed clinically that the larger the tumor mass the lower the likelihood of curing the patient, regardless of the treatment \[[@B17],[@B18]\]. Pathological and genetic heterogeneity increase with increasing tumor cell number and contribute to the emergence of clinical drug resistance \[[@B19]\]. As tumors grow larger their vascular surface decreases, intercapillary distance increases, interstial pressure increases and necrotic foci develop \[[@B20]\]. Tumor doubling times and cell loss also increase with increasing tumor size \[[@B17]\].

Implanted animal tumor models most likely represent clinical end-stage disease and may not necessarily recapitulate clinical behavior seen during tumor development in humans. There are few reports on the molecular and biochemical changes that occur as implanted solid tumors increase in size. Massaad *et al*. \[[@B21]\] found that some drug metabolizing enzyme systems, including glutathione-S-transferases (GST) did change both activity and expression with increasing tumor size in the mouse colon adenocarcinoma Co38.

Preclinical tumor models show variability in response to treatment with a given anti-tumor agent despite being derived from a single tumor and being implanted into inbred mice \[[@B22]\]. This has been attributed to heterogeneity of the host or the tumor cell populations \[[@B23],[@B24]\] along with tumor-to-tumor variations in perfusion and drug distribution \[[@B25]\]. We found there was no significant difference in gene expression between tumors of either the same size or different size as assessed in four replicate animals. If differences in tumor population, host metabolism or perfusion exist between animals implanted with the same tumors, our data suggests they are not detectable using gene expression analysis of the whole tumor.

Our results suggest that once tumor xenografts have grown to 200 mg, physiological influences on tumor transcription (such as the interaction with host stroma, nutrient supply and oxygenation) have reached steady state and do not change appreciably as the tumor grows to 1000 mg. It is also conceivable that tumors smaller and larger than the sizes investigated in this study may show gene expression changes. When a tumor is first implanted the hypoxic environment is likely to drive the expression of pro-angiogenic cytokines that will recruit new vessels to the tumor. As a tumor becomes very large (\>2 g) angiogenic factors may again become highly expressed due to the inability for the existing vasculature to adequately support the large tumor mass. We have not excluded the possibility that there may be changes in protein activities or levels, or that other tumor lines may show changes as the size increases. But since the phenomenon was independently observed in two tumor lines it suggests it may be common to many other lines. The results also imply that tumors harvested within this size range without drug treatment should be very comparable. It remains possible that selective isolation and analysis of tumor regions or subpopulations by microdissection may identify expression differences.

By comparing the same tumor line grown in different mouse strains we identified 63 genes with a significant change in gene expression with biological functions ranging from cellular signaling, RNA processing and translation. Although different genes were differentially expressed in different mouse strains, particular gene functions did not associate with one strain. Therefore, the biological significance of these changes remains unclear. It should be noted that although the changes were statistically significant, in general the magnitude of the change was small. Only 12% of the significant genes displayed a change greater or equal to 2-fold. This raises the question of whether statistical significance equates to biological significance and how relevant thresholds can be determined for analyzing expression profiling data.

In the second part of the study we compared the gene expression patterns of tumor lines grown as xenografts with the same lines grown in tissue culture. We found that each xenograft -- tissue culture pair was more similar to one another than any other line. This has been previously observed with RNA expression profiling of small cell lung cancer lines grown as both xenografts and tissue culture \[[@B3]\]. In our data, the one exception to this clustering pattern, ZR-75-1, exhibited aberrant growth characteristics; it had a rapid doubling time (2--3 days) and was not estrogen dependent as has been reported \[[@B26],[@B27]\].

There was a gene expression pattern consistent with growth either in a xenograft or tissue culture environment, but remarkably it consisted of only a small number of genes. We identified 36 genes with high relative expression in xenograft samples and 17 genes with high relative expression in tissue culture samples. Their biological functions were consistent with the differences between a tissue culture sample and a xenograft sample. Genes expressed at increased levels in tissue culture samples were primarily involved in cell division, cell cycle, transcription and translation and were consistent with a greater percentage of cycling cells in the tissue culture samples, which we have previously observed with flow cytometry (data not shown). Many of the genes expressed in xenograft samples encoded for proteins involved in extracellular matrix, cell adhesion, cell surface receptors transcription and translation and suggest increased interactions with an *in vivo*stromal environment, including the development of a 3-dimensional matrix.

There are several reports in the literature of tumor line expression profiling studies demonstrating that lines derived from a common tissue of origin group together in most cases \[[@B1],[@B4],[@B5]\]. We observed that most of the breast tumor lines clustered together but the other lines generally did not show clustering patterns based upon tissue of origin. However, our study evaluated fewer samples and consisted predominantly of breast cancer tumor lines with only two representatives of non-small cell lung cancer and colon cancer.

Since each tumor line was substantially different to every other line tesed it suggests that it would be possible to identify a group of genes that could be used to distinguish individual lines. Also, it has been our experience that it is possible to identify aberrant samples resulting from labeling error by expression profiling that were missed by other methods. What is less clear is whether genetic drift causes changes in RNA expression that can be identified using RNA profiling technology. Recently a report has been published showing that MCF-7 sublines were substantially different to each other both at the genetic and RNA expression levels \[[@B28]\] suggesting that variation within individual lines can be identified. Given this, it seems reasonable that RNA expression profiling could be used as a comprehensive methodology for identifying aberrant or incorrectly labeled samples. This would provide an additional quality control tool to standardize tumor models and the *in vivo*testing of therapeutic agents.

Conclusions
===========

Our data suggest that the environment a tumor line is grown in can have a significant effect on gene expression even though tumor size has little or no effect for a subcutaneously grown solid tumor. Furthermore, an individual tumor line has an RNA expression pattern that clearly defines it from other lines even when grown in different environments such as tissue culture or *in vivo*. Routine RNA expression profiling of a selected set of genes could be used as a quality control tool for preclinical oncology studies and would allow the standardization of tumor models used worldwide.
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![**Multidimensional scaling plot of Colo205 and HCT-116 samples.**Multidimensional scaling plot showing the relatedness of individual samples from Colo205 and HCT-116 to each other in 2D space. The color indicates the size of the tumor sample when harvested: red, 200 mg; blue, 500 mg; black, 1000 mg. The size of text indicates the mouse strain the tumor was grown in: small, Nu/Nu; large, C.B-17 SCID. Samples that are more related to each other are closer together. For Colo205 five samples were analyzed.](1471-2407-4-35-1){#F1}

![**Expected verses observed number of significantly changed genes.**The graph shows the number of genes (y-axis) that fall into specific categories (x-axis) based on the ANOVA calculated p-values. The categories are as follows: *Predicted*, number of genes expected by chance alone; *Tumor line effect*, number of genes that fall within the specified ranges due to differences in the tumor line; *Tumor size effect*, number of genes that fall within the specified ranges due to changes in the tumor size; *Mouse strain effect*, number of genes that fall within the specified range due to changes in the mouse strain the tumors were grown in.](1471-2407-4-35-2){#F2}

![**P-value distribution/volcano plot of line and size effect.**Scatter plot with mean expression level (log 10) on the x-axis and -- p-value (log 10) on y-axis. Each gene is plotted twice, once for the p-value resulting from the tumor-line effect ANOVA (black) and once for the p-value resulting from the tumor-size effect ANOVA (red). The blue line represents a p-value of 0.01. Genes with a lower p-value (more significant) have a higher -- p-value log10. There are far more genes with significant p-values due to differences in the tumor lines than due to changes in tumor size.](1471-2407-4-35-3){#F3}

![**Hierarchical clustering analysis of 13 tumor lines grown in different environments.**Hierarchical clustering analysis showing the structure within the data of the 13 tissue culture samples (suffix -- TC) and 8 xenograft samples (suffix -- X). Samples are displayed vertically, genes are displayed horizontally. A dendrogram of relatedness of the samples is at the top in green. For any two samples, the vertical distance from the sample roots to the first node joining them is a measure of their similarity; the shorter the distance the more similar. The color in each cell of the table represents the median adjusted expression value of each gene. The color scale used to represent the expression ratios is shown on the right, with yellow indicating increased expression relative to the median and blue decreased.](1471-2407-4-35-4){#F4}

![**Heat-map plot of differential expressed genes in xenograft or tissue culture samples.**Heat-map plot showing the genes selected as differentially expressed between the tissue culture and xenograft samples. The samples are displayed vertically, genes are displayed horizontally. Yellow indicates high expression while blue indicates low expression, relative to the median expression for each gene across all samples](1471-2407-4-35-5){#F5}

###### 

Genes with high expression in HCT-116 tumors grown in C.B-17 SCID mice

  **Function**                               **Affymetrix Probe Set ID**   **ANOVA p-value**   **BH p-value^1^**   **Log2 FC^2^**   **Gene Symbol**   **LocusLink ID**   **Sequence Probe Derived From**   **Gene Title**
  ------------------------------------------ ----------------------------- ------------------- ------------------- ---------------- ----------------- ------------------ --------------------------------- ---------------------------------------------------------------------
  **Translation/RNA binding/RNA splicing**                                                                                                                                                                 
                                             34733_at                      0.00029             0.046               0.5              SF3A1             10291              X85237                            splicing factor 3a, subunit 1, 120 kDa
                                             34829_at                      0.00020             0.046               0.4              DKC1              1736               U59151                            dyskeratosis congenita 1, dyskerin
                                             35174_i\_at                   0.00020             0.046               0.4              EEF1A2            1917               X70940                            eukaryotic translation elongation factor 1 alpha 2
                                             37462_i\_at                   0.00013             0.042               0.5              SF3A2             8175               L21990                            splicing factor 3a, subunit 2, 66 kDa
                                             39047_at                      0.00007             0.030               0.5              SART3             9733               AB020880                          squamous cell carcinoma antigen recognised by T cells 3
                                             40490_at                      0.00041             0.049               0.7              DDX21             9188               U41387                            DEAD/H box polypeptide 21
  **Signal transduction**                                                                                                                                                                                  
                                             33887_at                      0.00029             0.046               0.5              HGS               9146               D84064                            hepatocyte growth factor-regulated tyrosine kinase substrate
                                             38019_at                      0.00002             0.028               1.0              CSNK1E            1454               L37043                            casein kinase 1, epsilon
                                             38779_r\_at                   0.00039             0.048               0.8              HDGF              3068               D16431                            hepatoma-derived growth factor
                                             40864_at                      0.00029             0.046               0.4              RAC1              5879               D25274                            ras-related C3 botulinum toxin substrate
  **Small Molecule transport**                                                                                                                                                                             
                                             32186_at                      0.00023             0.046               0.7              SLC7A5            8140               M80244                            solute carrier family 7, member 5
                                             36557_at                      0.00003             0.028               0.9              CACNB1            782                M92303                            calcium channel, voltage-dependent, beta 1 subunit
                                             38029_at                      0.00031             0.046               0.4              SLC3A2            6520               J02939                            solute carrier family, member 2
  **Protein Complex Assembly**                                                                                                                                                                             
                                             31842_at                      0.00044             0.050               0.5              BCS1L             617                AF038195                          BCS1-like (yeast)
                                             32575_at                      0.00019             0.046               0.4              NAP1L4            4676               U77456                            nucleosome assembly protein 1-like 4
  **Protein transport and folding**                                                                                                                                                                        
                                             36945_at                      0.00036             0.047               0.5              C12orf8           10961              X94910                            chromosome 12 open reading frame 8
                                             40756_at                      0.00017             0.046               0.4              NPM3              10360              AF081280                          nucleophosmin/nucleoplasmin, 3
  **Unknown or other functions**                                                                                                                                                                           
                                             31670_s\_at                   0.00023             0.046               0.3              SRP72             6731               U81554                            signal recognition particle 72 kDa
                                             34279_at                      0.00005             0.030               2.0              FLJ20719          55672              AL050141                          hypothetical protein FLJ20719
                                             36192_at                      0.00003             0.028               0.7              KIAA0193          9805               D83777                            KIAA0193 gene product
                                             36209_at                      0.00003             0.028               0.8              BRD2              6046               S78771                            bromodomain containing 2
                                             36210_g\_at                   0.00035             0.047               1.0              BRD2              6046               S78771                            bromodomain containing 2
                                             36668_at                      0.00035             0.047               0.4              DIA1              1727               M28713                            diaphorase (NADH)
                                             37907_at                      0.00006             0.030               0.4              F8A               8263               M34677                            coagulation factor VIII-associated
                                             38885_at                      0.00000             0.007               1.0              DNA2L             1763               D42046                            DNA2 DNA replication helicase 2-like
                                             39436_at                      0.00010             0.039               1.5              BNIP3L            665                AF079221                          BCL2/adenovirus E1B 19 kDa interacting protein 3-like
                                             39758_f\_at                   0.00030             0.046               0.4              LAMP1             3916               J04182                            lysosomal-associated membrane protein 1
                                             39832_at                      0.00007             0.030               0.5              ARS2              51593              AL096723                          arsenate resistance protein ARS2
                                             40589_at                      0.00041             0.049               0.9              SNTB2             6645               U40572                            syntrophin, beta 2
                                             40604_at                      0.00012             0.040               1.1              DYRK2             8445               Y13493                            dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2
                                             41062_at                      0.00028             0.046               0.7              NSPC1             84759              AA037278                          likely ortholog of mouse nervous system polycomb 1
                                             982_at                        0.00011             0.039               0.4              MCM5              4174               X74795                            MCM5 minichromosome maintenance deficient 5, cell division cycle 46

^1^p-value resulting from Benjamini and Hochberg procedure ^2^log2 fold change calculated by dividing expression level from C.B-17 SCID sample by expression level of Nu/Nu sample

###### 

Genes with high expression in HCT-116 tumors grown in Nu/Nu mice

  **Function**                               **Affymetrix Probe Set ID**   **ANOVA p-value**   **BH p-value^1^**   **Log2 FC^2^**   **Gene Symbol**   **LocusLink ID**   **Sequence Probe Derived From**   **Gene Title**
  ------------------------------------------ ----------------------------- ------------------- ------------------- ---------------- ----------------- ------------------ --------------------------------- ------------------------------------------------------------------
  **Translation/RNA binding/RNA splicing**                                                                                                                                                                 
                                             32276_at                      0.00036             0.047               -0.5             RPL32             6161               X03342                            ribosomal protein L32
                                             32432_f\_at                   0.00032             0.046               -0.6             RPL15             6138               L25899                            ribosomal protein L15
                                             33614_at                      0.00028             0.046               -0.5             RPL18A            6142               X80822                            ribosomal protein L18a
                                             33660_at                      0.00039             0.048               -0.5             RPL5              6125               U14966                            ribosomal protein L5
                                             34317_g\_at                   0.00029             0.046               -0.5             RPS15A            6210               W52024                            ribosomal protein S15a
                                             34345_at                      0.00043             0.049               -0.1             C20orf14          24148              AF026031                          chromosome 20 open reading frame 14
                                             398_at                        0.00029             0.046               -0.6             DDX18             8886               X98743                            DEAD/H box polypeptide 18 (Myc-regulated)
                                             40887_g\_at                   0.00017             0.046               -0.5             EEF1A1            1915               L41498                            eukaryotic translation elongation factor 1 alpha 1
  **Signal Transduction**                                                                                                                                                                                  
                                             35772_at                      0.00029             0.046               -0.9             ARHGEF12          23365              AB002380                          Rho guanine nucleotide exchange factor (GEF) 12
                                             36091_at                      0.00038             0.048               -0.6             SCAP2             8935               AF051323                          src family associated phosphoprotein 2
                                             40784_at                      0.00003             0.028               -0.7             PPP2R5C           5527               Z69030                            protein phosphatase 2, regulatory subunit B (B56), gamma isoform
                                             769_s\_at                     0.00032             0.046               -0.3             ANXA2             302                D00017                            annexin A2
                                             777_at                        0.00010             0.039               -0.6             GDI2              2665               D13988                            GDP dissociation inhibitor 2
  **Unknown or Other Functions**                                                                                                                                                                           
                                             1160_at                       0.00024             0.046               -0.3             CYC1              1537               J04444                            cytochrome c-1
                                             1226_at                       0.00010             0.039               -0.5             ADAM17            6868               U69611                            a disintegrin and metalloproteinase domain 17
                                             31531_g\_at                   0.00007             0.030               -0.5             ACACB             32                 U89344                            acetyl-Coenzyme A carboxylase beta
                                             31684_at                      0.00004             0.030               -0.8             ANXA2P1           303                M62896                            annexin A2 pseudogene 1
                                             32518_at                      0.00014             0.042               -0.6             ZNF259            8882               AF019767                          zinc finger protein 259
                                             33363_at                      0.00041             0.049               -0.1             JTV1              7965               W25934                            JTV1 gene
                                             33389_at                      0.00017             0.046               -1.0             CYP51             1595               U23942                            cytochrome P450, 51
                                             33558_at                      0.00012             0.039               -0.5             TBX5              6910               Y09445                            T-box 5
                                             33820_g\_at                   0.00000             0.007               -0.7             HSPA8             3312               X13794                            heat shock 70 kDa protein 8
                                             33937_at                      0.00021             0.046               -0.6                                                  AJ011981                          Homo sapiens mRNA sequence, IMAGE clone 417820
                                             34808_at                      0.00022             0.046               -0.4                                                  AB023216                          KIAA0999 protein
                                             37218_at                      0.00029             0.046               -0.4             BTG3              10950              D64110                            BTG family, member 3
                                             38553_r\_at                   0.00025             0.046               -1.3             BAP29             55973              AI984786                          B-cell receptor-associated protein BAP29
                                             38589_i\_at                   0.00042             0.049               -0.6             PTMA              5757               M14630                            prothymosin, alpha (gene sequence 28)
                                             39167_r\_at                   0.00045             0.050               -1.2             SERPINH2          872                D83174                            serine (or cysteine) proteinase inhibitor, clade H, member 2
                                             418_at                        0.00004             0.030               -0.5             MKI67             4288               X65550                            antigen identified by monoclonal antibody Ki-67
                                             893_at                        0.00003             0.028               -0.4             E2-EPF            27338              M91670                            ubiquitin carrier protein
                                             932_i\_at                     0.00031             0.046               -0.8             ZNF91             7644               L11672                            zinc finger protein 91

^1^p-value resulting from Benjamini and Hochberg procedure ^2^log2 fold change calculated by dividing expression level from C.B-17 SCID sample by expression level of Nu/Nu sample

###### 

Human tumor lines used in this study

  **Tumor**    **Tissue of Origin**   **Xenograft sample**   **Tissue culture sample**
  ------------ ---------------------- ---------------------- ---------------------------
  BT-474       Breast                 No                     Yes
  MCF-7        Breast                 No                     Yes
  MDA-MB-231   Breast                 Yes                    Yes
  MDA-MB-435   Breast                 Yes                    Yes
  MDA-MB-453   Breast                 No                     Yes
  MDA-MB-468   Breast                 Yes                    Yes
  SKBr-3       Breast                 No                     Yes
  ZR-75-1      Breast                 Yes                    Yes
  Colo205      Colon                  Yes                    Yes
  HCT-116      Colon                  Yes                    Yes
  H125         Lung                   Yes                    Yes
  H2009        Lung                   No                     Yes
  A431         Squamous cell          Yes                    Yes

###### 

Number of genes with fold change values greater than or equal to 2 with tissue culture sample as the baseline

  **Tumor line**   **Number of genes with ≥2 fold increase**   **Number of genes with ≥2 fold decrease**   **Total with ≥2 fold change**
  ---------------- ------------------------------------------- ------------------------------------------- -------------------------------
  A431             542                                         650                                         1192
  Colo205          447                                         328                                         775
  H125             335                                         304                                         639
  HCT-116          351                                         393                                         744
  MDA-MB-231       489                                         381                                         870
  MDA-MB-435       404                                         519                                         923
  MDA-MB-468       381                                         204                                         585
  ZR-75-1          889                                         1218                                        2107
  **Median**       425.5                                       387                                         822.5

###### 

Genes with high expression in xenograft samples

  **Function**                               **Affymetrix Probe Set ID**   **Gene Symbol**   **LocusLink ID**   **Sequence Probe Set Derived From**   **Gene Title**
  ------------------------------------------ ----------------------------- ----------------- ------------------ ------------------------------------- --------------------------------------------------------------------
  **Extracellular Matrix/Cell Adhesion**                                                                                                              
                                             31574_i\_at                                                        M14087                                Beta-galactoside-binding lectin, mRNA sequence
                                             31810_g\_at                   CNTN1             1272               Z21488                                contactin 1
                                             32305_at                      COL1A2            1278               J03464                                collagen, type I, alpha 2
                                             32701_at                      ARVCF             421                U51269                                armadillo repeat gene deletes in velocardiofacial syndrome
                                             36298_at                      PRPH              5630               L14565                                peripherin
                                             38181_at                      MMP11             4320               X57766                                matrix metalloproteinase 11 (stromelysin 3)
                                             38570_at                      HLA-DOB           3112               X03066                                major histocompatibility complex, class II, DO beta
                                             38614_s\_at                   OGT               8473               U77413                                O-linked N-acetylglucosamine (GlcNAc) transferase
  **Cell surface receptor**                                                                                                                           
                                             33950_g\_at                   CRHR2             1395               AF011406                              corticotropin releasing hormone receptor 2
                                             35485_at                      GRM4              2914               X80818                                glutamate receptor, metabotropic 4
                                             35503_at                      HTR1B             3351               M81590                                5-hydroxytryptamine (serotonin) receptor 1B
                                             36277_at                      CD3E              916                M23323                                CD3E antigen, epsilon polypeptide (TiT3 complex)
                                             41190_at                      TNFRSF25          8718               U83598                                tumor necrosis factor receptor superfamily, member 25
  **Tanscription/transcription factor**                                                                                                               
                                             34786_at                      JMJD1             55818              AB018285                              zinc finger protein
                                             36944_f\_at                   PLAGL1            5325               U72621                                pleiomorphic adenoma gene-like 1
                                             37491_at                      TAF1              6872               D90359                                TAF1 RNA polymerase II, TATA box binding protein-associated factor
                                             38216_at                      TRIP8             9323               L40411                                thyroid hormone receptor interactor 8
  **Intracellular transport**                                                                                                                         
                                             32228_at                      AP2A2             161                AB020706                              adaptor-related protein complex 2, alpha 2 subunit
                                             33779_at                      VAMP1             6843               AF060538                              vesicle-associated membrane protein 1 (synaptobrevin 1)
  **Translation/RNA binding/RNA splicing**                                                                                                            
                                             1556_at                       RBM5              10181              U23946                                RNA binding motif protein 5
                                             31896_at                      NAG               51594              AL050281                              neuroblastoma-amplified protein
  **Unknown or other functions**                                                                                                                      
                                             1155_at                                                            J03069                                
                                             1529_at                       13CDNA73          10129              U50534                                hypothetical protein CG003
                                             31525_s\_at                                                        J00153                                
                                             31652_at                      KIAA1000          22989              AB023217                              KIAA1000 protein
                                             32355_at                      DKFZP564D166      26115              AL050270                              putative ankyrin-repeat containing protein
                                             36811_at                                                           U24389                                
                                             37979_at                      YAP1              10413              X80507                                Yes-associated protein 1, 65 kDa
                                             39499_s\_at                   PARD3             56288              W25794                                par-3 partitioning defective 3 homolog
                                             40928_at                      WSB1              26118              W26496                                SOCS box-containing WD protein SWiP-1
                                             41113_at                      KIAA0557          26048              AI871396                              KIAA0557 protein
                                             41328_s\_at                   EML2              24139              AL096717                              echinoderm microtubule associated protein like 2
                                             40856_at                      SERPINF1          5176               U29953                                serine (or cysteine) proteinase inhibitor, clade F, member 1
                                             32833_at                      CLK1              1195               M59287                                CDC-like kinase 1
                                             39451_i\_at                   IDS               3423               AF050145                              iduronate 2-sulfatase (Hunter syndrome)
                                             36386_at                      PDK1              5163               L42450                                pyruvate dehydrogenase kinase, isoenzyme 1

###### 

Genes with high expression in tissue culture samples

  **Function**                               **Affymetrix ProbeSet ID**   **Gene Symbol**   **LocusLink ID**   **Sequence ProbeSet Derived From**   **Gene Title**
  ------------------------------------------ ---------------------------- ----------------- ------------------ ------------------------------------ --------------------------------------------------------------------
  **Cell division**                                                                                                                                 
                                             34851_at                     STK6              6790               AF011468                             serine/threonine kinase 6
                                             33346_r\_at                  TUBG1             7283               M61764                               tubulin, gamma 1
                                             35995_at                     ZWINT             11130              AF067656                             ZW10 interactor
                                             37171_at                     KNSL5             9493               X67155                               kinesin-like 5 (mitotic kinesin-like protein 1)
  **Cell cycle**                                                                                                                                    
                                             34736_at                     CCNB1             891                M25753                               cyclin B1
                                             37458_at                     CDC45L            8318               AJ223728                             CDC45 cell division cycle 45-like (S. cerevisiae)
                                             38804_at                     CSE1L             1434               AF053641                             CSE1 chromosome segregation 1-like (yeast)
  **Translation/RNA binding/RNA splicing**                                                                                                          
                                             35323_at                     EIF3S9            8662               U78525                               eukaryotic translation initiation factor 3, subunit 9 eta, 116 kDa
                                             38679_g\_at                  SNRPE             6635               AA733050                             small nuclear ribonucleoprotein polypeptide E
                                             41460_at                     RBM14             10432              AF080561                             RNA binding motif protein 14
  **Transcription/transcription factor**                                                                                                            
                                             39664_at                     CKN1              1161               U28413                               Cockayne syndrome 1 (classical)
                                             41332_at                     POLR2E            5434               D38251                               polymerase (RNA) II (DNA directed) polypeptide E, 25 kDa
  **Unknown or other functions**                                                                                                                    
                                             35715_at                     DKFZP564M082      25906              AL080071                             DKFZP564M082 protein
                                             40758_at                     ICT1              3396               X81788                               immature colon carcinoma transcript 1
                                             1749_at                      GCDH              2639               AD000092                             glutaryl-Coenzyme A dehydrogenase
                                             40134_at                     ATP5J2            9551               AF047436                             ATP synthase, subunit f, isoform 2
                                             41400_at                     TK1               7083               K02581                               thymidine kinase 1, soluble
